Skip to Content

Durvalumab

In the US, Durvalumab (durvalumab systemic) is a member of the drug class anti-PD-1 monoclonal antibodies and is used to treat Non-Small Cell Lung Cancer and Urothelial Carcinoma.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XC28

CAS registry number (Chemical Abstracts Service)

1428935-60-7

Chemical Formula

C6502-H10018-N1742-O2024-S42

Molecular Weight

146320

Therapeutic Category

Antineoplastic agent: Monoclonal antibody

Chemical Name

Immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MEDI4736 heavy chain), disulfide with human monoclonal MEDI4736 kappa-chain, dimer (USAN)

Foreign Names

  • Durvalumabum (Latin)
  • Durvalumab (German)
  • Durvalumab (French)
  • Durvalumab (Spanish)

Generic Names

  • Durvalumab (OS: USAN)
  • MEDI 4736 (ChemID) (IS)
  • MEDI4736 (ChemID) (IS)
  • MEDI-4736 (Stoffliste) (IS)
  • UNII-28X28X9OKV (ChemID) (IS)

Brand Names

Glossary

TermDefinition
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide